Literature DB >> 23007713

Exploring arterial smooth muscle Kv7 potassium channel function using patch clamp electrophysiology and pressure myography.

Lioubov I Brueggemann1, Bharath K Mani, Jennifer Haick, Kenneth L Byron.   

Abstract

Contraction or relaxation of smooth muscle cells within the walls of resistance arteries determines the artery diameter and thereby controls flow of blood through the vessel and contributes to systemic blood pressure. The contraction process is regulated primarily by cytosolic calcium concentration ([Ca(2+)](cyt)), which is in turn controlled by a variety of ion transporters and channels. Ion channels are common intermediates in signal transduction pathways activated by vasoactive hormones to effect vasoconstriction or vasodilation. And ion channels are often targeted by therapeutic agents either intentionally (e.g. calcium channel blockers used to induce vasodilation and lower blood pressure) or unintentionally (e.g. to induce unwanted cardiovascular side effects). Kv7 (KCNQ) voltage-activated potassium channels have recently been implicated as important physiological and therapeutic targets for regulation of smooth muscle contraction. To elucidate the specific roles of Kv7 channels in both physiological signal transduction and in the actions of therapeutic agents, we need to study how their activity is modulated at the cellular level as well as evaluate their contribution in the context of the intact artery. The rat mesenteric arteries provide a useful model system. The arteries can be easily dissected, cleaned of connective tissue, and used to prepare isolated arterial myocytes for patch clamp electrophysiology, or cannulated and pressurized for measurements of vasoconstrictor/vasodilator responses under relatively physiological conditions. Here we describe the methods used for both types of measurements and provide some examples of how the experimental design can be integrated to provide a clearer understanding of the roles of these ion channels in the regulation of vascular tone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007713      PMCID: PMC3490242          DOI: 10.3791/4263

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  10 in total

1.  Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal.

Authors:  B M Altura
Journal:  J Pharmacol Exp Ther       Date:  1975-05       Impact factor: 4.030

2.  TTX-sensitive voltage-gated Na+ channels are expressed in mesenteric artery smooth muscle cells.

Authors:  Roberto Berra-Romani; Mordecai P Blaustein; Donald R Matteson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07       Impact factor: 4.733

3.  Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways.

Authors:  Kyle K Henderson; Kenneth L Byron
Journal:  J Appl Physiol (1985)       Date:  2007-01-04

4.  Effects of big endothelin-1 in comparison with endothelin-1 on the microvascular blood flow velocity and diameter of rat mesentery in vivo.

Authors:  Mohamed Anwar Abdelhalim
Journal:  Microvasc Res       Date:  2006-10-09       Impact factor: 3.514

5.  Comparison of small artery sensitivity and morphology in pressurized and wire-mounted preparations.

Authors:  B J Falloon; N Stephens; J R Tulip; A M Heagerty
Journal:  Am J Physiol       Date:  1995-02

6.  Enhanced resistance artery sensitivity to agonists under isobaric compared with isometric conditions.

Authors:  W R Dunn; G C Wellman; J A Bevan
Journal:  Am J Physiol       Date:  1994-01

7.  Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Bharath K Mani; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2009-07-15       Impact factor: 4.436

8.  Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance.

Authors:  Alexander R Mackie; Lioubov I Brueggemann; Kyle K Henderson; Aaron J Shiels; Leanne L Cribbs; Karie E Scrogin; Kenneth L Byron
Journal:  J Pharmacol Exp Ther       Date:  2008-02-13       Impact factor: 4.030

9.  Differences in sensitivity of rat mesenteric small arteries to agonists when studied as ring preparations or as cannulated preparations.

Authors:  N H Buus; E VanBavel; M J Mulvany
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

10.  KCNQ/M currents in sensory neurons: significance for pain therapy.

Authors:  Gayle M Passmore; Alexander A Selyanko; Mohini Mistry; Mona Al-Qatari; Stephen J Marsh; Elizabeth A Matthews; Anthony H Dickenson; Terry A Brown; Stephen A Burbidge; Martin Main; David A Brown
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

  10 in total
  3 in total

1.  KV7 Channel Pharmacological Activation by the Novel Activator ML213: Role for Heteromeric KV7.4/KV7.5 Channels in Guinea Pig Detrusor Smooth Muscle Function.

Authors:  Aaron Provence; Damiano Angoli; Georgi V Petkov
Journal:  J Pharmacol Exp Ther       Date:  2017-10-30       Impact factor: 4.030

2.  Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α₁-adrenergic receptor function.

Authors:  Harold H Bach; Yee M Wong; Abhishek Tripathi; Amanda M Nevins; Richard L Gamelli; Brian F Volkman; Kenneth L Byron; Matthias Majetschak
Journal:  Mol Med       Date:  2014-10-13       Impact factor: 6.354

3.  Involvement of transglutaminase 2 and voltage-gated potassium channels in cystamine vasodilatation in rat mesenteric small arteries.

Authors:  Morten Engholm; Estéfano Pinilla; Susie Mogensen; Vladimir Matchkov; Elise Røge Hedegaard; Hua Chen; Michael J Mulvany; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2016-01-27       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.